Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
暂无分享,去创建一个
C. Flowers | L. Rubinstein | J. Doroshow | D. Chihara | S. Ivy | N. Takebe | L. Nastoupil | S. Finnigan | Nebojsa Skorupan | Y. Fukuda | L. Cordes | Erich P. Huang